Evidence for estrogen synthesis in adenomyotic tissues

Yamamoto, Takara; Noguchi, Toshifumi; Tamura, Takeyuki; Kitawaki, Jo; Okada, Hiroji

doi:10.1016/0002-9378(93)90654-2

Cited by 101 publications

(47 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In brief, danazol probably interacts with estrogen, progesterone and/or androgen receptors [18][19][20][21] and directly inhibits enzymes such as 3ß-hydroxysteroid dehydogenase, aromatase, and 17ß-hydroxysteroid dehydrogenase, which are involved in estrogen synthesis, which may have an impact on the growth of endometrial cancer [22][23][24].…”

Section: Discussionmentioning

confidence: 99%

Treatment of Endometrial Hyperplasia with a Danazol-Releasing Intrauterine Device: A Prospective Study

Tamaoka

Orikasa²,

Sumi³

et al. 2004

Gynecol Obstet Invest

View full text Add to dashboard Cite

The purpose of the present study was to assess the effect of a danazol-releasing intrauterine device (D-IUD) in the treatment of endometrial hyperplasia. Twenty patients with endometrial hyperplasia including 14 with simple endometrial hyperplasia and 2 with complex endometrial hyperplasia (group A), and 4 with atypical endometrial hyperplasia (group B) were enrolled in the prospective study between August 1999 and December 2003. During and just after the treatment, improvement was seen in all patients. Simple or complex endometrial hyperplasia (group A) demonstrated regression to a normal secretory endometrium (38% of group A), pseudodecidual stromal change (31%) and glandular atrophy (25%), and miscellaneous change (inflammation, necrosis, etc.) (38%). Atypical hyperplasia (group B) demonstrated regression to a normal secretory endometrium (25% of group B), pseudodecidual stromal change (75%), glandular atrophy (50%) and miscellaneous change (granulation) (25%). In group A, 2 women conceived after completion of the treatment. The recurrence rate in patients with endometrial hyperplasia (groups A and B) in the follow- up was 20% and acceptable as compared with other studies. The pretreatment menstrual interval patterns of the patients were maintained peri- and post-treatment. These data indicate that D-IUD therapy might be a novel and effective method for the treatment of endometrial hyperplasia.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Endometrial Hyperplasia with a Danazol-Releasing Intrauterine Device: A Prospective Study

Tamaoka

Orikasa²,

Sumi³

et al. 2004

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…It is similarly influenced by ovarian or extraovarian estrogens [22,23]. These ectopic endometriotic foci are more or less autonomous [24] and may have different hormonal sensitivity levels than the normal endometrium [25][26][27].…”

Section: Discussionmentioning

confidence: 99%

Estrogen and Progesterone Receptors of Adenomyosis in Postmenopausal Breast Cancer Patients Treated with Tamoxifen

Cohen¹,

Shapira²,

Beyth³

et al. 1998

Gynecol Obstet Invest

View full text Add to dashboard Cite

Adenomyosis is an ectopic endometrial tissue located in the myometrium. It has been reported to develop at a higher rate among postmenopausal breast cancer patients on tamoxifen (TAM) treatment than in untreated patients. It has also been reported to be stimulated by estrogen. Assessing receptor levels in adenomyotic tissue may indicate the adenomyotic cell’s potential to interact with TAM. In the present study the estrogen receptor (ER) and progesterone receptor (PR) were analyzed by an immunohistochemical technique in adenomyotic and the corresponding endometrial tissues of 14 postmenopausal breast cancer patients treated with TAM and in 15 healthy postmenopausal patients who served as controls. All TAM-treated patients had normal postmenopausal serum estradiol levels. Overall the ER and PR contents in adenomyotic tissue (42.9 and 71.4%) and in the endometriotic tissue (64.3 and 78.6%) obtained from the study patients were similar to those obtained from the control group (adenomyosis, ER and PR = 46.7 and 86.7%; endometrium, ER and PR = 40 and 73.3%; p = NS). In the study group, the ER content was lower in the adenomyotic (42.9%) than in the endometriotic tissue (64.3%). No correlation was found between the duration of TAM therapy, the TAM dosage level or the ER or PR content in the adenomyotic or endometrial tissues. The finding of a relatively low ER content in the adenomyotic tissue than in the endometriotic tissue in postmenopausal TAM-treated patients without endogenous estrogens, similar to that observed in healthy premenopausal women, may be attributed to the estrogen-like effect of TAM.

show abstract

“…Dieses Enzym, welches Testosteron und Androstendion in Estradiol bzw. Estron umwandelt, konnte vermehrt im Endometrium von Frauen mit Endometriose und im Stroma von Endometrioseherden sowie in adenomyotischem Gewebe nachgewiesen werden und führt zu lokal erhöhten Östrogen-gewebsspiegeln (Yamamoto et al 1993;Noble et al 1996Noble et al , 1997Kitawaki et al 1997). Dies paût zu dem Befund erhöhter Östrogenspiegel im Menstrualblut von Frauen mit Endometriose und Adenomyose im Vergleich zu solchen gesunder Frauen, während die jeweiligen Östrogenspie-gel im Blut sich nicht unterscheiden (Takahashi et al 1989).…”

Section: Das Eutope Endometrium Bei Endometrioseunclassified

“…In diesem Zusammenhang ist der Befund einer pathologischen Expression der P450Aromatase in adenomyotischem Gewebe, in Endometrioseherden und im eutopen Endometrium von Frauen mit Endometriose von Bedeutung (Noble et al 1996;1997;Kitawaki et al 1997). Diese Enzym katalysiert die Bildung von Östradiol und Östron aus Testosteron und Androstendion und führt somit zu einer pathologischen Erhöhung der Östrogenge-websspiegel am Ort ihrer Expression (Yamamoto et al 1993), während sich die peripheren Östrogenspiegel von Frauen mit und ohne Endometriose nicht unterscheiden (Leyendecker et al 1996). Erste Ergebnisse (Becker et al, in Vorbereitung) weisen darauf hin, daû die P450Aromatase in der frühen Proliferations kurzzeitig exprimiert wird.…”

Section: Pathogenese Von Adenomyose Und Endometrioseunclassified

Die Archimetra als neues morphologisch-funktionelles Konzept des Uterus sowie als Ort der Primärerkrankung bei Endometriose

Leyendecker

Kunz

Noe

et al. 1999

Reproduktionsmedizin

View full text Add to dashboard Cite

Evidence for estrogen synthesis in adenomyotic tissues

Cited by 101 publications

References 13 publications

Treatment of Endometrial Hyperplasia with a Danazol-Releasing Intrauterine Device: A Prospective Study

Treatment of Endometrial Hyperplasia with a Danazol-Releasing Intrauterine Device: A Prospective Study

Estrogen and Progesterone Receptors of Adenomyosis in Postmenopausal Breast Cancer Patients Treated with Tamoxifen

Die Archimetra als neues morphologisch-funktionelles Konzept des Uterus sowie als Ort der Primärerkrankung bei Endometriose

Contact Info

Product

Resources

About